Paul Aisen is in fact on Anavex's SAB (to answer your rhetorical question). Here is the information posted on Anavex's SAB listing to refresh our memories.
Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, "Single Endpoint for New Drug Approvals for Alzheimer's Disease," urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer's disease.